Leveraging a scalable, standardized platform process for suspension-based AAV and LV vector manufacture to accelerate time to clinic
Cell & Gene Therapy Insights 2022; 8(7), 791
Published: 29 July 2022
- Common challenges in the development and commercialization of viral vector products
- Advantages of choosing a platform process approach for your viral vector product
- Overview of the Patheon™ Quick to Clinic™ viral vector program components
- Summary of key performance metrics for Quick to Clinic™ including process yield, impurity profile, etc.